Clinical Edge Journal Scan

Breast MRI less accurate in predicting nodal status after neoadjuvant therapy in invasive lobular carcinoma


 

Key clinical point: Preoperative breast magnetic resonance imaging (MRI) has low accuracy in predicting nodal status after neoadjuvant therapy in patients with invasive lobular carcinoma (ILC), suggesting that axillary findings on posttreatment breast MRI should not be used to plan surgical approach to the axilla.

Major finding: Overall, the accuracy of posttreatment breast MRI in predicting axillary nodal status ranged from 45.5% to 66.7%. The overall accuracy of MRI for predicting nodal status was similar among patients treated with neoadjuvant endocrine therapy (ET) vs. chemotherapy (66.7% vs. 50%; P = .1393).

Study details : Findings are from a retrospective analysis of 79 women with stage I-III ILC who underwent preoperative breast MRI after either neoadjuvant chemotherapy (n=46) or ET (n=33).

Disclosures: This publication was supported by the National Center for Advancing Translational Sciences, National Institute of Health. The authors declared no conflicts of interest.

Source: Abel MK et al. NPJ Breast Cancer. 2021 Mar 5. doi: 10.1038/s41523-021-00233-9 .

Recommended Reading

FDA scrutinizes cancer therapies granted accelerated approval
Breast Cancer ICYMI
Most breast cancer screening centers not following guidelines
Breast Cancer ICYMI
Could tamoxifen dose be slashed down to 2.5 mg? 
Breast Cancer ICYMI
Huge, struggling breast cancer screening trial gets lifeline
Breast Cancer ICYMI
Risk-based mammography proposed for times of reduced capacity
Breast Cancer ICYMI
Early breast cancer: Updated MINDACT findings back omitting chemotherapy in low genomic risk
Breast Cancer ICYMI
Early breast cancer: Updated MINDACT findings back omitting chemotherapy in low genomic risk
Breast Cancer ICYMI
Pembrolizumab fails to improve OS in patients with previously treated metastatic TNBC
Breast Cancer ICYMI
Node-negative ER+/HER2− breast cancer: Adjuvant ET improves OS in older patients with comorbidities
Breast Cancer ICYMI
Advanced breast cancer: Palbociclib+ET associated with low burden of cutaneous toxicities
Breast Cancer ICYMI